[Skip to Content]
[Skip to Content Landing]

Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Is the BNT162b2 SARS-CoV-2 vaccine safe in children younger than 5 years?

Findings  In this cohort study based on a survey of guardian-reported safety profiles of BNT162b2 in 7806 children, higher dosages of BNT162b2 were significantly associated with injection-site reactions. Compared with approved non–SARS-CoV-2 vaccines, BNT162b2 was associated with significantly more frequent injection-site, musculoskeletal, dermatologic, or otolaryngologic symptoms but fewer general symptoms and fever after vaccination.

Meaning  In this study, the overall frequency of adverse events after vaccination with BNT162b2 was comparable with the frequency of adverse events after vaccination with approved non–SARS-CoV-2 vaccines in children younger than 5 years.

Abstract

Importance  SARS-CoV-2 vaccines are authorized for use in most age groups. The safety of SARS-CoV-2 vaccines is unknown in children younger than 5 years.

Objective  To retrospectively evaluate the safety of the BNT162b2 vaccine used off-label in children younger than 5 years compared with the safety of non–SARS-CoV-2 vaccines in the same sample.

Design, Setting, and Participants  This investigator-initiated retrospective cohort study included parents or caregivers who registered children for SARS-CoV-2 vaccination in outpatient care facilities in Germany. The study was performed as an authenticated online survey. A total of 19 000 email addresses were contacted from vaccination registration databases between April 14 and May 9, 2022. Inclusion criteria were child age younger than 5 years at the first BNT162b2 vaccination and use of a correct authentication code to prove invitation.

Exposures  Off-label BNT162b2 vaccination and on-label non–SARS-CoV-2 vaccinations.

Main Outcomes and Measures  Reported short-term safety data of 1 to 3 doses of 3 to 10 μg BNT162b2 in children from birth to younger than 60 months are presented. Coprimary outcomes were the frequencies of 11 categories of symptoms after vaccination with bivariate analyses and regression models adjusting for age, sex, weight, and height.

Results  The study included 7806 children (median age, 3 years [IQR, 2-4 years]; 3824 [49.0%] female) who were followed up of for a mean (SD) of 91.4 (38.8) days since first BNT162b2 vaccination (survey response rate, 41.1%). A 10-μg dosage was more frequently associated with local injection-site symptoms compared with lower dosages. In the active-comparator analysis, the probability of any symptoms (odds ratio [OR], 1.62; 95% CI, 1.43-1.84), local symptoms (OR, 1.68; 95% CI, 1.38-2.05), musculoskeletal symptoms (OR, 2.55; 95% CI, 1.32-4.94), dermatologic symptoms (OR, 2.18; 95% CI, 10.7-4.45), or otolaryngologic symptoms (OR, 6.37; 95% CI, 1.50-27.09) were modestly elevated after BNT162b2 compared with non–SARS-CoV-2 vaccines, whereas the probabilities of general symptoms (OR, 0.77; 95% CI, 0.63-0.95) and fever (OR, 0.42; 95% CI, 0.32-0.55) were lower after BNT162b2. Symptoms requiring hospitalization (n = 10) were reported only at BNT162b2 dosages above 3 μg.

Conclusions and Relevance  In this cohort study, the symptoms reported after BNT162b2 administration were comparable overall to those for on-label non–SARS-CoV-2 vaccines in this cohort of children younger than 5 years. The present data may be used together with prospective licensure studies of BNT162b2 efficacy and safety and could help guide expert recommendations about BNT162b2 vaccinations in this age group.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: August 31, 2022.

Published: October 18, 2022. doi:10.1001/jamanetworkopen.2022.37140

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Toepfner N et al. JAMA Network Open.

Corresponding Author: Cho-Ming Chao, MD, PhD, Department of Pediatrics, HELIOS University Medical Center, Witten/Herdecke University, Heusnerstr 40, 42283 Wuppertal, Germany (unichao@yahoo.de).

Author Contributions: Drs Strumann and Chao had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Toepfner and von Meißner are co–first authors. Drs M.B. Moor and Chao are co–senior authors.

Concept and design: Toepfner, von Meißner, J. Moor, M.B. Moor, Chao.

Acquisition, analysis, or interpretation of data: Toepfner, von Meißner, Strumann, Drinka, Berner, M.B. Moor, Chao.

Drafting of the manuscript: Toepfner, von Meißner, Strumann, Drinka, Stuppe, Jorczyk, J. Moor, Püschel, Liss, Poblotzki, Berner, M.B. Moor, Chao.

Critical revision of the manuscript for important intellectual content: Toepfner, von Meißner, Strumann, J. Moor, Berner, M.B. Moor, Chao.

Statistical analysis: Strumann.

Administrative, technical, or material support: Toepfner, von Meißner, Drinka, Stuppe, Jorczyk, Püschel, Liss, Chao.

Supervision: Toepfner, Chao.

Design of the questionnaire: Toepfner, von Meißner, Drinka, Stuppe, Jorczyk, J. Moor, M.B. Moor, Chao.

Conflict of Interest Disclosures: Dr J. Moor reported receiving funding from the Swiss Society of General Internal Medicine Foundation and the Swiss Academy of Medical Sciences outside the submitted work. Drs Drinka, Toepfner, and Berner and Mr Jorczyk were supported by University Medical Center Dresden. Dr M. B. Moor was supported by University Hospital Bern and the National Competence Center of Research-Kidney. Dr Chao was supported by University Medical Center Rostock. No other disclosures were reported.

Additional Contributions: The authors are thankful to all participating vaccination centers and respondents. We acknowledge the nonprofit assistance for participant recruitment provided by the Bildung Aber Sicher and U12Schutz initiatives and by Anke Böhnke, MD (Frauenarztpraxis, Berlin, Germany), Armin Philipp, MD (Hautarztpraxis, Stuttgart, Germany), Georg Hillebrand, MD (Klinik für Kinder- und Jugendmedizin, Itzehoe, Germany), Lisa Degener, MD (Hausärztliche Gemeinschaftspraxis, Altenberge, Germany), and Lisa Schneider, MD (Gemeinschaftspraxis Dres Albrecht/Winkler, Laupheim, Germany). No one was compensated for their work.

References
1.
Fang  SF , Liu  N , Du  HW .  BNT162b2 Covid-19 vaccine in children 5 to 11 years of age.   N Engl J Med. 2022;386(6):604. doi:10.1056/NEJMc2118775 PubMedGoogle ScholarCrossref
2.
Walter  EB , Talaat  KR , Sabharwal  C ,  et al; C4591007 Clinical Trial Group.  Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age.   N Engl J Med. 2022;386(1):35-46. doi:10.1056/NEJMoa2116298 PubMedGoogle ScholarCrossref
3.
Frenck  RW  Jr , Klein  NP , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents.   N Engl J Med. 2021;385(3):239-250. doi:10.1056/NEJMoa2107456 PubMedGoogle ScholarCrossref
4.
Cohen-Stavi  CJ , Magen  O , Barda  N ,  et al.  BNT162b2 vaccine effectiveness against omicron in children 5 to 11 years of age.   N Engl J Med. 2022;387(3):227-236. doi:10.1056/NEJMoa2205011 PubMedGoogle ScholarCrossref
5.
Tan  SHX , Cook  AR , Heng  D , Ong  B , Lye  DC , Tan  KB .  Effectiveness of BNT162b2 vaccine against omicron in children 5 to 11 years of age.   N Engl J Med. 2022;387(6):525-532. doi:10.1056/NEJMoa2203209 PubMedGoogle ScholarCrossref
6.
Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY | Pfizer. Accessed August 20, 2022. https://www.pfizer.com/news/announcements/pfizer-and-biontech-submit-variation-ema-vaccination-children-6-months-less-than-5-years
7.
US Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine. Published July 13, 2022. Accessed August 20, 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine
8.
Christmann  K . Neues Portal will Impfungen für unter Zwölfjährige befördern. Der Tagesspiegel Online. Published November 21, 2021. Accessed May 11, 2022. https://www.tagesspiegel.de/wissen/kontaktanbahnung-und-beratung-neues-portal-will-impfungen-fuer-unter-zwoelfjaehrige-befoerdern/27819890.html
9.
Heroisch, leichtsinnig oder einfach das Richtige?: Deshalb impfen Ärzte schon jetzt Kinder unter zwölf Jahren gegen Corona. Published July 31, 2021. Accessed May 11, 2022. https://plus.tagesspiegel.de/wissen/heroisch-oder-leichtsinnig-warum-manche-aerzte-jetzt-schon-kleine-kinder-gegen-corona-impfen-201203.html
10.
Aktuell  SWR . Ärzte in Baiersbronn haben schon 900 Kinder gegen Corona geimpft. swr.online. Accessed May 11, 2022. https://www.swr.de/swraktuell/baden-wuerttemberg/tuebingen/baiersbronner-aerzte-impfen-kinder-seit-langem-gegen-corona-100.html
11.
Delay in COVID-19 vaccines for kids upset parents. Experts say it was the right thing to do. USA Today. Accessed May 11, 2022. https://www.usatoday.com/story/news/2022/02/21/pfizer-covid-vaccine-kids-under-5-fda-delay/6789369001/
12.
Off-Label-Use – Verordnungsfähigkeit von Arzneimitteln in nicht zugelassenen Anwendungsbieten - Gemeinsamer Bundesausschuss. Accessed May 11, 2022. https://www.g-ba.de/themen/arzneimittel/arzneimittel-richtlinie-anlagen/off-label-use/
13.
Schutzimpfungen außerhalb der Zulassung (Off-Label-Use). Deutsches Grünes Kreuz für Gesundheit e.V. Accessed May 11, 2022. https://dgk.de/fachleute/dgk-fachnewsletter/schutzimpfungen-ausserhalb-der-zulassung-off-label-use.html
14.
Rodeck  B . 7. Stellungnahme des ExpertInnenrates der Bundesregierung zu COVID-19. Published February 17, 2022. Accessed September 10, 2022. https://www.bundesregierung.de/resource/blob/974430/2006266/47d5893828bc9d1ab4d07ed41b7cb078/2022-02-17-siebte-stellungnahme-expertenrat-data.pdf?download=1
15.
Corona-ExpertInnenrat | Bundesregierung. Webseite der Bundesregierung | Startseite. Accessed May 5, 2022. https://www.bundesregierung.de/breg-de/bundesregierung/bundeskanzleramt/corona-expertinnenrat-der-bundesregierung
16.
German Clinical Trials Register. Survey of side effects after vaccination (Comirnaty, BNT162b2) against COVID-19 in children below 5 Years in Germany. DRKS00028759. Accessed September 9, 2022. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00028759
17.
World Medical Association.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.   JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053PubMedGoogle ScholarCrossref
18.
Harris  PA , Taylor  R , Thielke  R , Payne  J , Gonzalez  N , Conde  JG .  Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support.   J Biomed Inform. 2009;42(2):377-381. doi:10.1016/j.jbi.2008.08.010 PubMedGoogle ScholarCrossref
19.
Shuhama  R , Del-Ben  CM , Loureiro  SR , Graeff  FG .  Defensive responses to threat scenarios in Brazilians reproduce the pattern of Hawaiian Americans and non-human mammals.   Braz J Med Biol Res. 2008;41(4):324-332. doi:10.1590/S0100-879X2008000400011 PubMedGoogle ScholarCrossref
21.
ClinicalTrials.gov. Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against Covid-19 in Healthy Children and Young Adults. NCT04816643. Accessed April 19, 2022. https://clinicaltrials.gov/ct2/show/NCT04816643
22.
Paul-Ehrlich-Institut. Coronavirus und COVID-19 - Sicherheit von COVID-19-Impfstoffen. Accessed May 10, 2022. https://www.pei.de/DE/newsroom/dossier/coronavirus/arzneimittelsicherheit.html
23.
Yackey  K , Stukus  K , Cohen  D , Kline  D , Zhao  S , Stanley  R .  Off-label medication prescribing patterns in pediatrics: an update.   Hosp Pediatr. 2019;9(3):186-193. doi:10.1542/hpeds.2018-0168 PubMedGoogle ScholarCrossref
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close